Figure 2.

Modulation of mortality by Tocilizumab. Mortality was measured for whole groups of critically (black bars), severely (grey bars) and moderately-ill (white bars) and compared with controls having a similar disease severity (a), but severely and moderately-ill patients were further stratified by administration of the drug within different disease stages (b) and drug doses used (c). Finally, a qualitative multivariate analysis was performed by plotting the severely-ill surviving patients by disease stage and dose used (red, blue and green dots), as well as the severely-ill diseased patients (orange dots) (d). Mortality was expressed as percentage and significant differences were measured by a Fisher’s exact test, and considered as such when p ≤ 0.05. Tcz Tocilizumab; ST standard treatment; VS viral stage; EIS early inflammatory stage; LIS late inflammatory stage.